{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Small Business", "lead_paragraph": "A LITTLE-NOTICED provision in the Medicare prescription drug law passed by Congress late last year is starting to shake up the group insurance market for small businesses. The provision created health savings accounts that allow people to set aside pretax income to pay medical bills. When linked to high-deductible insurance policies, the accounts, known as H.S.A.'s, can drastically lower an employer's costs of providing employee health benefits. This may allow more small businesses to offer such benefits -- or provide savings for those that already do.", "headline": {"main": "Weighing the Risks in a Health Savings Account", "kicker": "INSURANCE"}, "abstract": "Little noticed provision of Medicare prescription drug law that created health savings accounts, letting people set aside pretax income to pay medical bills, is beginning to shake up group insurance market for small businesses; accounts, when linked to high-deductible insurance policies, can drastically lower employer's costs of providing employee health benefits; proponents say lower cost may spur more small businesses to offer employee benefits (special section, Small Business) (M)", "print_page": "3", "word_count": 1145, "_id": "4fd247f08eb7c8105d7e3d3c", "snippet": "A little-noticed provision in the Medicare prescription drug law passed by Congress late last year is starting to shake up the group insurance market for small businesses.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/09/21/business/businessspecial/21BROC.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "FRINGE BENEFITS"}, {"name": "subject", "value": "HEALTH INSURANCE AND MANAGED CARE"}, {"name": "subject", "value": "INSURANCE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "MEDICARE"}, {"name": "subject", "value": "SMALL BUSINESS"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Fred", "rank": 1, "lastname": "BROCK"}], "original": "By FRED BROCK"}, "document_type": "article", "pub_date": "2004-09-21T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Health & Fitness", "lead_paragraph": "Last week, a federal advisory panel urged regulators to warn parents that antidepressant drugs not only increase the risk of suicide in some children, but that most have a poor track record in curing their disease. The recommendation came after a yearlong debate over whether the drugs are as safe and effective as advertised. It was based on evidence that a small minority of children show increased signs of suicidal behavior when taking the drugs.", "headline": {"main": "Is Prozac Better? Is It Even Different?"}, "abstract": "Federal advisory panel, looking into concerns that some antidepressant drugs could increase risk of suicide in young people, suggests that drugs have labels warning patents of possible risks; Prozac, which was first antidepressant of its class, remains only antidepressant approved by Food and Drug Administration for treatment of depression in children and adolescents; Dr Steven Hyman, National Institute of Mental Health former director, holds that since Prozac works on same principle as other drugs in its class there should be no difference in how they impact patients; clinical trials on Prozac and possible reasons why drug might work differently discussed; suicide risk is highest for antidepressants in first three to four weeks of treatment; photo (L)", "print_page": "1", "word_count": 1584, "_id": "4fd2801a8eb7c8105d84abbc", "snippet": "Through all the recent warnings about antidepressants and children, one of the drugs seemed somehow above the fray: Prozac. But is it really that different?", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/09/21/health/psychology/21proz.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "HYMAN, STEVEN"}, {"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "organizations", "value": "NATIONAL INSTITUTE OF MENTAL HEALTH"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "LABELING AND LABELS"}, {"name": "subject", "value": "CONSUMER PROTECTION"}, {"name": "subject", "value": "ANTIDEPRESSANTS"}, {"name": "subject", "value": "MENTAL HEALTH AND DISORDERS"}, {"name": "subject", "value": "PROZAC (DRUG)"}, {"name": "subject", "value": "TESTS AND TESTING"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}, {"name": "subject", "value": "CHILDREN AND YOUTH"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "DEPRESSION (MENTAL)"}, {"name": "subject", "value": "SUICIDES AND SUICIDE ATTEMPTS"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Benedict", "rank": 1, "lastname": "CAREY"}], "original": "By BENEDICT CAREY"}, "document_type": "article", "pub_date": "2004-09-21T00:00:00Z", "section_name": "Health"}, {"type_of_material": "Op-Ed", "blog": [], "news_desk": "Editorial Desk", "lead_paragraph": "Measures to make the results of drug trials more accessible to doctors and the public, as well as the federal government's probable stiffer warnings on the use of antidepressants for children, are definitely steps in the right direction. But my experience as a family doctor on the front lines of medicine leads me to believe that these moves won't be enough to curb the influence of the drug companies on our health care. The impetus for these changes comes largely from revelations in the Food and Drug Administration's review of the new class of antidepressants, known as selective serotonin reuptake inhibitors, in the treatment of depression in children and adolescents. Many studies, the review found, show that the drugs are no more effective than placebos, but significantly increase the risk of suicidal tendencies. So why are doctors writing millions of prescriptions each year to treat depressed children with these drugs?", "headline": {"main": "Information Is the Best Medicine", "kicker": "Op-Ed Contributor"}, "abstract": "John Abramson Op-Ed article contends proposal by medical journals to publish results only of registered studies will not be enough to resolve problem of lack of transparency in clinical drug trials; contends only way to curb drug industry's domination of medical knowledge is to establish oversight board to evaluate scientific evidence independently and make recommendations to define standards of medical care", "print_page": "15", "word_count": 1040, "_id": "4fd2a4818eb7c8105d88a92e", "snippet": "Merely making the results of drug trials more accessible won't be enough to curb the influence of drug companies.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/09/18/opinion/18abramson_.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "CONSUMER PROTECTION"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "John", "rank": 1, "lastname": "Abramson"}], "original": "By John Abramson"}, "document_type": "article", "pub_date": "2004-09-18T00:00:00Z", "section_name": "Health; Opinion"}, {"type_of_material": "Letter", "blog": [], "news_desk": "Editorial Desk", "lead_paragraph": "To the Editor: As a father whose son died by suicide 12 years ago, I was interested in your article about the link between antidepressants and suicide.", "headline": {"main": "Antidepressants and Suicide"}, "abstract": "Dennis Gates letter responds to Sept 14 article on antidepressants; finds it ironic that worst side effect is most likely to afflict those most likely to benefit from drugs", "print_page": "14", "word_count": 103, "_id": "4fd2a4818eb7c8105d88a931", "snippet": "To the Editor:    As a father whose son died by suicide 12 years ago, I was interested in your article about the link between antidepressants and suicide.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://query.nytimes.com/gst/fullpage.html?res=9C06EED81739F93BA2575AC0A9629C8B63", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "GATES, DENNIS"}, {"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "CHILDREN AND YOUTH"}, {"name": "subject", "value": "MENTAL HEALTH AND DISORDERS"}, {"name": "subject", "value": "ANTIDEPRESSANTS"}, {"name": "subject", "value": "DEPRESSION (MENTAL)"}, {"name": "subject", "value": "SUICIDES AND SUICIDE ATTEMPTS"}], "byline": null, "document_type": "article", "pub_date": "2004-09-18T00:00:00Z", "section_name": "Opinion"}, {"type_of_material": "Letter", "blog": [], "news_desk": "Editorial Desk", "lead_paragraph": "To the Editor: Antidepressants can be lifesaving but, as has become sadly clear, can also on rare occasion precipitate suicide. Unfortunately, these powerful medications are prescribed, with very good intentions, by physicians who may not be able to see the patient again for quite some time.", "headline": {"main": "Antidepressants and Suicide"}, "abstract": "Dr Deborah Young letter, responding to Sept 14 article on antidepressants, warns antidepressants are prescribed for people who are not at logical, decision-making best and thus may fail to call doctor about noxious side effects", "print_page": "14", "word_count": 181, "_id": "4fd23cb38eb7c8105d7d2363", "snippet": "To the Editor:    Antidepressants can be lifesaving but, as has become sadly clear, can also on rare occasion precipitate suicide. Unfortunately, these powerful medications are prescribed, with very good intentions, by physicians who may not be able...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://query.nytimes.com/gst/fullpage.html?res=9501EED81739F93BA2575AC0A9629C8B63", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "YOUNG, DEBORAH DR)"}, {"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "CHILDREN AND YOUTH"}, {"name": "subject", "value": "MENTAL HEALTH AND DISORDERS"}, {"name": "subject", "value": "DEPRESSION (MENTAL)"}, {"name": "subject", "value": "SUICIDES AND SUICIDE ATTEMPTS"}], "byline": null, "document_type": "article", "pub_date": "2004-09-18T00:00:00Z", "section_name": "Opinion"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "Psychiatrists, pediatricians and family practice doctors said in interviews that they would restrict their use of antidepressants in the wake of a federal advisory committee's decision that the medicines should contain severe warnings about the risks of suicide. Dr. Alexander Lerman, a child and adolescent psychiatrist in New York City, said that he would no longer prescribe the medicines to some children and that for the rest he would sit down with their parents and discuss in detail the risks of the drugs.", "headline": {"main": "Doctors Say They Will Cut Antidepressant Use"}, "abstract": "Psychiatrists, pediatricians and family practice doctors say they will restrict their use of antidepressants in wake of federal advisory committee's decision that medicines should contain severe warnings about risks of suicide (M)", "print_page": "18", "word_count": 942, "_id": "4fd254dd8eb7c8105d7fc74b", "snippet": "Doctors said that they would restrict the use of antidepressants for children in the wake of a decision that the medicines should contain severe warnings about suicide risks.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/09/16/health/16depress.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "CHILDREN AND YOUTH"}, {"name": "subject", "value": "LABELING AND LABELS"}, {"name": "subject", "value": "MENTAL HEALTH AND DISORDERS"}, {"name": "subject", "value": "ANTIDEPRESSANTS"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "DEPRESSION (MENTAL)"}, {"name": "subject", "value": "SUICIDES AND SUICIDE ATTEMPTS"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Gardiner", "rank": 1, "lastname": "HARRIS"}], "original": "By GARDINER HARRIS"}, "document_type": "article", "pub_date": "2004-09-16T00:00:00Z", "section_name": "Health; U.S."}], "meta": {"hits": 6, "offset": 0, "time": 35}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}